Presentation

Sciex Discovery Continuum Seminar, Sept. 18, 2025

Play button Biomarkers for Evaluating Parkinson’s Disease and Assessing Drug Efficacy

Press Release

Nextcea files patent infringement litigation against Lipotype Inc (US) and Lipotype GmbH (Germany).

US patent ribbon US Patent No. 8,313,949

Bloomberg Law

reports Nextcea Patent Suit Targets Lipotype Fat-Based Diagnostic Tests
Complaint Exhibit A Exhibit B Exhibit C

Applied biomarker services to neurodegenerative diseases

Biomarker and drug target engagement services including Parkinson’s, Gaucher disease, Dementia, Leukemia

Globally focused with pharmaceuticals across the world

Drug efficacy PK/PD and safety assessments via plasma, CSF, and urine for clinical and non-clinical studies

Nextcea performs Drug Efficacy & Safety Assessments
using proprietary biomarkers through advanced LC-MS/MS platforms

LRRK2

Parkinson’s disease

GBA

Parkinson’s disease & Gaucher disease

BTK

Leukemia / Lymphoma

Phospholipidosis

Drug-Induced Phospholipidosis / Parkinsonism

Nextcea is dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development.

Kidney Safety Assessment

for Oligonucleotide drug candidates